MSTN and obesity disorder: They also displayed increased expression of AMPK and phosphorylation within skeletal muscle with consecutive activation of PGC1α and Fndc5 (irisin precursor), demonstrating that targeting myostatin could be effective in treating obesity and metabolic syndrome [154].